Yantai Dongcheng Pharmaceutical Co Ltd (002675) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Yantai Dongcheng Pharmaceutical Co Ltd (002675) has a cash flow conversion efficiency ratio of 0.042x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥239.54 Million ≈ $35.05 Million USD) by net assets (CN¥5.66 Billion ≈ $827.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Yantai Dongcheng Pharmaceutical Co Ltd's balance sheet to measure how much of total assets are equity-financed.
Yantai Dongcheng Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Yantai Dongcheng Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Yantai Dongcheng Pharmaceutical Co Ltd to evaluate the quality of earnings relative to operating cash generation.
Yantai Dongcheng Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Yantai Dongcheng Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dalian Huarui Heavy Industry Group Co Ltd
SHE:002204
|
-0.016x |
|
Odontoprev S.A
SA:ODPV3
|
0.005x |
|
Bukit Asam Tbk PT
JK:PTBA
|
0.087x |
|
Coursera Inc
NYSE:COUR
|
0.023x |
|
Mesoblast Limited
F:LWB
|
-0.028x |
|
Zhejiang Expressway Co. Ltd
F:ZHJ
|
0.012x |
|
Maxvision Technology Corp
SHE:002990
|
0.031x |
|
Solvac S.A.
BR:SOLV
|
0.011x |
Annual Cash Flow Conversion Efficiency for Yantai Dongcheng Pharmaceutical Co Ltd (2008–2025)
The table below shows the annual cash flow conversion efficiency of Yantai Dongcheng Pharmaceutical Co Ltd from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see 002675 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥5.66 Billion ≈ $827.65 Million |
CN¥584.61 Million ≈ $85.55 Million |
0.103x | +93.35% |
| 2024-12-31 | CN¥5.37 Billion ≈ $786.01 Million |
CN¥287.15 Million ≈ $42.02 Million |
0.053x | +4.15% |
| 2023-12-31 | CN¥5.40 Billion ≈ $789.55 Million |
CN¥276.94 Million ≈ $40.53 Million |
0.051x | -72.79% |
| 2022-12-31 | CN¥5.28 Billion ≈ $772.97 Million |
CN¥996.54 Million ≈ $145.82 Million |
0.189x | +0.44% |
| 2021-12-31 | CN¥5.02 Billion ≈ $735.14 Million |
CN¥943.58 Million ≈ $138.08 Million |
0.188x | +62.89% |
| 2020-12-31 | CN¥4.97 Billion ≈ $726.63 Million |
CN¥572.58 Million ≈ $83.79 Million |
0.115x | -20.87% |
| 2019-12-31 | CN¥4.78 Billion ≈ $699.31 Million |
CN¥696.38 Million ≈ $101.90 Million |
0.146x | +36.26% |
| 2018-12-31 | CN¥4.61 Billion ≈ $674.68 Million |
CN¥493.06 Million ≈ $72.15 Million |
0.107x | +68.33% |
| 2017-12-31 | CN¥3.29 Billion ≈ $481.25 Million |
CN¥208.94 Million ≈ $30.57 Million |
0.064x | -0.18% |
| 2016-12-31 | CN¥3.08 Billion ≈ $451.28 Million |
CN¥196.28 Million ≈ $28.72 Million |
0.064x | +113.39% |
| 2015-12-31 | CN¥2.24 Billion ≈ $327.19 Million |
CN¥66.69 Million ≈ $9.76 Million |
0.030x | -32.08% |
| 2014-12-31 | CN¥1.18 Billion ≈ $173.30 Million |
CN¥52.00 Million ≈ $7.61 Million |
0.044x | +334.72% |
| 2013-12-31 | CN¥1.10 Billion ≈ $161.16 Million |
CN¥-20.60 Million ≈ $-3.01 Million |
-0.019x | -142.66% |
| 2012-12-31 | CN¥1.02 Billion ≈ $148.60 Million |
CN¥44.53 Million ≈ $6.52 Million |
0.044x | -90.38% |
| 2011-12-31 | CN¥304.42 Million ≈ $44.55 Million |
CN¥138.83 Million ≈ $20.31 Million |
0.456x | +52.81% |
| 2010-12-31 | CN¥191.06 Million ≈ $27.96 Million |
CN¥57.02 Million ≈ $8.34 Million |
0.298x | +257.54% |
| 2009-12-31 | CN¥140.43 Million ≈ $20.55 Million |
CN¥-26.60 Million ≈ $-3.89 Million |
-0.189x | -136.16% |
| 2008-12-31 | CN¥79.34 Million ≈ $11.61 Million |
CN¥41.57 Million ≈ $6.08 Million |
0.524x | -- |
About Yantai Dongcheng Pharmaceutical Co Ltd
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. engages in the raw materials, formulations, nuclear medicine, and big health businesses in China and internationally. It operates through API, Formulation, Radio Pharmaceutical, and Others segments. The company offers formulation products, such as powder injections, tablets, capsules, granules, and drop pills for anticoagulation, cardiovascular, anti… Read more